Healthcare provider profile · identity verified

Binu K.C., MD

Internal Medicine · SAN JOSE, CA · NPI 1962866947

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	422	161
Amlodipine Besylate	Amlodipine Besylate	279	102
Losartan Potassium	Losartan Potassium	257	81
Lisinopril	Lisinopril	227	85
Albuterol Sulfate Hfa	Albuterol Sulfate	171	87
Levothyroxine Sodium	Levothyroxine Sodium	148	54
Metoprolol Tartrate	Metoprolol Tartrate	122	48
Fluticasone Propionate	Fluticasone Propionate	114	63
Hydrochlorothiazide	Hydrochlorothiazide	114	42
Tamsulosin Hcl	Tamsulosin Hcl	107	33
Omeprazole	Omeprazole	102	43
Atenolol	Atenolol	81	29
Gabapentin	Gabapentin	81	33
Trazodone Hcl	Trazodone Hcl	81	26
Alendronate Sodium	Alendronate Sodium	80	33
Simvastatin	Simvastatin	79	33
Wixela Inhub	Fluticasone Propion/Salmeterol	78	21
Furosemide	Furosemide	76	32
Famotidine	Famotidine	72	31
Tizanidine Hcl	Tizanidine Hcl	72	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	71	26
Metformin Hcl	Metformin Hcl	71	30
Alvesco	Ciclesonide	70	31
Metformin Hcl Er	Metformin Hcl	64	26
Lovastatin	Lovastatin	63	24
Pantoprazole Sodium	Pantoprazole Sodium	60	21
Ibuprofen	Ibuprofen	44	26
Terazosin Hcl	Terazosin Hcl	41	14
Citalopram Hbr	Citalopram Hydrobromide	40	11
Glipizide	Glipizide	40	16
Chlorthalidone	Chlorthalidone	39	11
Duloxetine Hcl	Duloxetine Hcl	37	18
Meloxicam	Meloxicam	37	16
Triamcinolone Acetonide	Triamcinolone Acetonide	37	22
Allopurinol	Allopurinol	35	14
Metoprolol Succinate	Metoprolol Succinate	35	16
Rosuvastatin Calcium	Rosuvastatin Calcium	32	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	31	13
Naproxen	Naproxen	30	13
Spiriva Respimat	Tiotropium Bromide	30	13
Hydralazine Hcl	Hydralazine Hcl	29	15
Montelukast Sodium	Montelukast Sodium	29	13
Pradaxa	Dabigatran Etexilate Mesylate	29	suppressed
Prednisone	Prednisone	29	23
Jardiance	Empagliflozin	28	11
Azithromycin	Azithromycin	27	23
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Potassium Chloride	Potassium Chloride	27	11
Sertraline Hcl	Sertraline Hcl	27	11
Humulin N	Insulin Nph Human Isophane	26	13
Tramadol Hcl	Tramadol Hcl	26	suppressed
Clopidogrel	Clopidogrel Bisulfate	25	12
Propranolol Hcl	Propranolol Hcl	25	suppressed
Baclofen	Baclofen	24	suppressed
Cefadroxil	Cefadroxil	24	19
Finasteride	Finasteride	24	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	23	suppressed
Mupirocin	Mupirocin	22	suppressed
Carvedilol	Carvedilol	20	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	17
Hydrocortisone	Hydrocortisone	17	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	15
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Temazepam	Temazepam	14	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Breyna	Budesonide/Formoterol Fumarate	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error